In preparation for the pending commercial launch of Oralin in ecuador, Generex Biotechnology Corporation hosted a press conference yesterday afternoon at its Toronto offices to provide the European press with an overview of the Company and its proprietary buccal drug delivery platform technologies, particularly the status of the clinical and regulatory global development program for Oralin, its proprietary oral insulin buccal spray for the treatment of both type 1 and type 2 diabetes.

A webcast of the press conference is available here. To dial in and listen to the webcast please call 1-706-643-7496 .